Amendia launched the Syzygyâ„¢ Stabilization System, intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion.Â
Study results support the biocompatibility of Rotation Medical’s collagen-based bioinductive implant and its ability to promote new connective tissue with the appearance of tendon.
Spineology launched a range of TLIF technologies for use with the Anatomy-Conserving Medial Lumbar Interbody Fusion platform (ACT MediaLIF™). These technologies support TLIF placement of interbody devices using a direct posterior approach.
Regentis Biomaterials received FDAÂ Investigational Device Exemption approval to initiate a pivotal Phase III clinical study of its GelrinC procedure to treat focal knee cartilage defects.
joimax’s TESSYS® transforaminal and iLESSYS® interlaminar procedures are fully covered in the U.S. following release of a new CPT 2017 Codebook by the American Medical Association.Â
The Musculoskeletal Transplant Foundation is now sole tissue provider for Spineology’s allograft product lines, including the newly-launched Incite™ Cortical Fiber bone graft.
Spineway signed a 5-year agreement with TINAVI Medical for distribution of spinal implants and instruments in China. TINAVI’s TiRobotâ„¢ is reported to be the only surgical robot capable of addressing surgery on all spinal regions.Â
In observing the lineup of spine revenue over $100 million halfway through the year, NuVasive stands at the forefront of growth while pure-play companies like Globus and K2M are outperforming their diversified peers in the field.
In 1H16, 21 companies received their first orthopaedic-related 510(k). Of these, ten were bestowed for spinal products. Of those ten companies, only four are slated to appear on the NASS floor this year.